Abstract:Abstract Abstract 140 Background Arsenic trioxide increases the rate of complete remission (CR) and prolongs long-term overall survival in patients with acute promyelocytic leukemia (APL). We demonstrated that an oral arsenic-containing Realgar-Indigo naturalis formula (RIF) could yield clear synergistic effects in an in vivo murine APL model as well as an in vitro APL cell lines. The efficacy and safety of this formula were confirmed by a CR rate of 96.7% and reasonable safety profile in a multicenter Phase II clinical trial in China. To find out whether oral RIF could achieve similar remission and survival with ATO, the Chinese APL Cooperative Group conducted a phase 3 randomized study (APL07) that compared oral RIF with ATO in both the induction and maintenance therapies. Methods In this phase 3 randomized trial, 242 newly diagnosed APL patients were randomly assigned to receive oral RIF (n=121, daily 60 mg per kg body weight) or ATO (n=121, daily 0.15 mg per kg body weight) as a part of induction therapy. All patients also received all-trans-retinoic acid (ATRA; daily 25 mg per square meter) as induction therapy, and were between the ages of 15 and 60 years. After achieving CR, all patients were given three courses of consolidation chemotherapy with anthracycline and cytosine arabinoside. The maintenance treatment included eight cycles of sequential use of ATRA and RIF or ATO for two years. The primary endpoint was disease-free survival (DFS). The secondary endpoints were the rate of CR and overall survival (OS) and safety. Results At a median follow-up of 28 months, no significant differences were noted between RIF group and ATO group with respect to CR rate (99.1% vs.97.2%, P=0.62), DFS (98.9% vs.97.64%, P=0.6) (Figure 1A) and OS at 3 years (99.1% vs.96.6%, P=0.18) (Figure 1B). The rates of adverse events were similar in the two groups. The rate of treatment-related grade 3/4 liver toxic effects was 9.6% in the RIF group and 12.0% in the ATO group(p=0.67). When on the arsenic-containing treatment, the plasma arsenic content was higher in the ATO group than in the RIF group (56.3 vs. 23.6 μg/L, p=0.0002). The median levels of arsenics concentration of plasm, urine, hair and nail samples after completing therapy 12 months were below the lower limit of the normal control. Conclusions Oral Realgar-Indigo naturalis formula yielded a comparable high remission and long-term survival with arsenic trioxide as front-line treatment of newly diagnosed APL. Disclosures: No relevant conflicts of interest to declare.

Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide

Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide

Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide

HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells

Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide

Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Distribution And Speciation Of Arsenic After Intravenous Administration Of Monomethylmonothioarsonic Acid In Rats

Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate of Remission and Survival to Intravenous Arsenic Trioxide As a Front-Line Treatment in Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial APL07

Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Arsenic Trioxide Replacing or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)

All-Trans Retinoic Acid Plus Arsenic Trioxide Versus All-Trans Retinoic Acid Plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis

The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.

Biotransformation of Arsenic Trioxide by AS3MT Favors Eradication of Acute Promyelocytic Leukemia: Revealing the Hidden Facts

Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells

Role of Arsenic (+3 Oxidation State) Methyltransferase in Arsenic Mediated APL Treatment: an in Vitro Investigation.

Balance Between the Toxicity and Anticancer Activity of Arsenic Trioxide in Treatment of Acute Promyelocytic Leukemia.

Trivalent Methylated Arsenic Metabolites Induce Apoptosis in Human Myeloid Leukemic HL-60 Cells Through Generation of Reactive Oxygen Species

Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment